Policicchio Benjamin Bruno, Sette Paola, Xu Cuiling, Haret-Richter George, Dunsmore Tammy, Pandrea Ivona, Ribeiro Ruy M, Apetrei Cristian
Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pennsylvania, United States of America.
PLoS One. 2018 Feb 21;13(2):e0190908. doi: 10.1371/journal.pone.0190908. eCollection 2018.
Two SIVmac251-infected rhesus macaques received tenofovir/emtricitabine with raltegravir intensification. Viral rebound occurred during treatment and sequencing of reverse transcriptase and integrase genes identified multiple resistance mutations. Similar to HIV infection, antiretroviral-resistance mutations may occur in SIV-infected nonhuman primates receiving nonsuppressive ART. As ART administration to nonhuman primates is currently dramatically expanding, fueled by both cure research and the study of HIV-related comorbidities, viral resistance should be factored in the study design and data interpretation.
两只感染了SIVmac251的恒河猴接受了替诺福韦/恩曲他滨联合拉替拉韦强化治疗。治疗期间出现了病毒反弹,对逆转录酶和整合酶基因进行测序发现了多个耐药突变。与HIV感染相似,接受无效抗逆转录病毒治疗的感染SIV的非人灵长类动物可能会出现抗逆转录病毒耐药突变。由于目前在治愈研究和HIV相关合并症研究的推动下,对非人灵长类动物进行抗逆转录病毒治疗的应用正在大幅增加,因此在研究设计和数据解读中应考虑病毒耐药性。